Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Nov 16 - Nov 21
The MVPs finalized for the CY 2025 performance period/2027 MIPS payment year contain an average of 14 quality measures for MVP Participants to select from, ranging from 8 to 24 quality measures in each MVP (89 FR 98972 through 99056)
Rare but serious gastrointestinal risks associated with GLP-1 receptor agonists include intestinal obstruction and ileus
Potential role of Nrf 2 activators with dual antiviral and anti-inflammatory properties in the management of viral pneumonia
The Phase 2 trial (NCT04881760) tested multiple dose escalation strategies, and the Phase 3 TRIUMPH program refined these into the most effective approach
US$ 24.27
US$ 20.28
US$ 27.55
US$ 27.88
US$ 29.88
US$ 29.64
US$ 20.18
